Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-08-03 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
独立董事关于第五届董事会第十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various board meeting matters, including extending the validity of a convertible bond issuance plan, reappointment of the audit firm for 2023, appointment of senior management, cancellation of stock options, capital increase and amendment of the company charter, and credit facility applications by subsidiaries. It references the fifth board's twelfth meeting and includes detailed opinions on governance and compliance with laws and regulations. The content focuses on board and management decisions and approvals rather than financial results or audit reports themselves. The document is not a full audit report, annual report, or earnings release, nor is it a simple announcement or certification. It fits best under Board/Management Information (MANG) as it deals with board meeting matters and management appointments.
2023-08-03 Chinese
关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for convening the 2023 first extraordinary general meeting (临时股东大会) of Yunnan Watson Biotechnology Co., Ltd. It includes details about the meeting date, voting procedures, proposals to be discussed, and registration methods. It does not contain financial statements or results but is an announcement about the meeting and the agenda items to be voted on. The document length is 3917 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI).
2023-08-03 Chinese
公司章程（2023年8月）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 云南沃森生物技术股份有限公司 dated August 2023. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance-related rules. There is no financial data, earnings information, audit results, or capital raising updates. The content is focused on the internal governance framework and rules of the company. This matches the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2023-08-03 Chinese
关于增加公司注册资本并修订公司章程的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding an increase in registered capital and amendments to the company's articles of association (company charter). It details the board meeting decisions, changes in share capital due to stock option exercises, and revisions to governance provisions including ESG responsibilities. The document does not contain financial statements or detailed financial performance data but rather corporate governance and capital structure updates. It is a formal announcement of corporate actions requiring shareholder approval and subsequent registration changes. This fits the category of Share Issue/Capital Change (SHA) as it concerns changes in registered capital and related corporate governance amendments.
2023-08-03 Chinese
独立董事关于续聘公司2023年度审计机构的事前认可意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the reappointment of the company's audit firm for the 2023 fiscal year. It references compliance with regulatory rules and the company's articles of association, and it discusses the qualifications and integrity of the audit firm. The document does not contain actual financial statements or audit results but is an approval or endorsement related to the audit process. This fits the category of an Audit Report / Information (AR) as it pertains to audit-related information but is not a full annual report or financial statement. The document length is short and focused on audit firm reappointment, not a report publication announcement or regulatory filing. Therefore, the best classification is AR with high confidence. FY 2023
2023-08-03 Chinese
关于子公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's subsidiaries applying for comprehensive credit facilities from banks. It details the credit amounts, purposes, and approvals from the board and supervisory committee. The document does not contain full financial statements or detailed financial performance reports but rather focuses on financing activities and approvals. It is not a full annual or interim report, nor is it a simple notice of report publication. The content fits the category of Capital/Financing Update as it provides updates on financing activities and credit applications by subsidiaries.
2023-08-03 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.